On November 4th, the journalist noticed that the National Enterprise Credit Information Publicity System showed that there was a change in the person in charge (legal representative, person in charge, chief representative, partner in charge, etc.) of AstraZeneca Pharmaceutical Co., Ltd., from Wang Lei to MAQDOSI EWA, with the change date being October 11, 2024. On the same day, there were changes in the market entity type and investors of AstraZeneca Pharmaceutical Co., Ltd. The market entity type changed from a limited liability company (Sino-foreign joint venture) to a limited liability company (foreign legal person sole proprietorship). The investor changes (including contribution amount, contribution method, contribution date, investor name, etc.) changed from Xinfajituan Co., Ltd. of Wuxi City, Jiangsu Wuxi Pharmaceuticals Co., Ltd., AstraZeneca Continent B.V. to AstraZeneca Continent B.V. On October 30th, AstraZeneca's global website and China's official website announced that AstraZeneca's Global Executive Vice President, Chairman of International Business, and China's President, Wang Lei, is cooperating with the investigation in China. (The Paper News)